Two preclinical CAR-T constructs, RJ154-HL and 3A11, utilizing distinct single-chain variable fragments (scFvs) specific for FGFR4, have demonstrated potent anti-tumor activity. The gene discussed is FGFR4; the disease is neoplasm.